Advertisement

 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links

advertisement.gif (61x7 -- 0 bytes)

   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 

 

 

Chronic myeloid leukemia
Pathology

The Philadelphia chromosome

The Ph1 results from a reciprocal translocation between the long arms of chromosomes 9 and 22 t(9;22)(q34;q11) and is demonstrable in all hematopoietic precursors. This in turn results in a fused bcr-abl gene and in the production of an abnormal tyrosine kinase protein that causes the disordered myelopoiesis found in CML.

  • In chromosome 9: The c-abl proto-oncogene located in chromosome 9q34 encodes for a nonreceptor protein-tyrosine kinase expressed in most mammalian cells.
  • In chromosome 22: The breakpoint occurs within the BCR gene and usually involves an area known as the breakpoint cluster region (bcr), located either between exons b3 and b4 or between exons b2 and b3.
  • The fusion: There are two different fusion genes can be formed, both of them joining exon 2 of abl with either exon 2 (b2a2) or exon 3 of bcr (b3a2).

Upon translation, a new protein with a molecular weight of 210 kd (p210BCR-ABL) is synthesized, which, compared to the normal c-abl, has markedly increased kinase activity and can transform transfected cells and induce leukemia in transgenic mice. The mechanism of oncogenesis of p210BCR-ABL is unclear, but, upon phosphorylation, it can activate several intracellular pathways, including ras and the MAP kinase pathway, the Jak-Stat pathway, the PI3 kinase pathway, and the myc pathway. Ultimately, this leads to altered adhesion to extracellular matrix and stroma, constitutive activation of mitogenic signals, and inhibition of apoptosis.

Philadelphia negative CML

Philadelphia negative CML differs from typical CML and may be a different disease. The age profile is different with the Philadelphia negative variety favoring young children and elderly persons. The leucocyte and platelet counts tend to be lower. The bone marrow tends to show more immature cells in the myeloid series. The NAP score is higher. The prognosis of this type of CML is poorer.

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


Clonality

Clonal studies have demonstrated that CML is a clonal disease of an abnormal stem cell. Myeloid, erythroid, megakaryocytic and most lymphoid cells are involved in the malignant clone.

previous.gif (72x17 -- 347 bytes) next.gif (72x17 -- 277 bytes)

 

 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright © 2001-2007 The Doctors Lounge. All rights reserved.